Safety and efficacy of etanercept beyond 10 years of therapy in North American patients with early and longstanding rheumatoid arthritis

Arthritis Care and Research

Volumn 63, Issue 3, 2011, Pages 373-382

  Weinblatt, Michael E ^a   Bathon, Joan M ^b   Kremer, Joel M ^c   Fleischmann, Roy M ^d   Schiff, Michael H ^e   Martin, Richard W ^f   Baumgartner, Scott W ^g   Park, Grace S ^g   Mancini, Edward L ^g   Genovese, Mark C ^h  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b Och Spine at New York Presbyterian Hospitals   (United States)

^c ALBANY MEDICAL COLLEGE   (United States)

^d UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^e UNIVERSITY OF COLORADO   (United States)

^f MICHIGAN STATE UNIVERSITY   (United States)

^g AMGEN INC   (United States)

^h STANFORD UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; CORTICOSTEROID; DISEASE MODIFYING ANTIRHEUMATIC DRUG; ETANERCEPT; METHOTREXATE; ANTIRHEUMATIC AGENT; IMMUNOGLOBULIN G; TNFR FC FUSION PROTEIN; TNFR-FC FUSION PROTEIN; TUMOR NECROSIS FACTOR RECEPTOR;

ADULT; AGED; ANGINA PECTORIS; ARTICLE; ATYPICAL MYCOBACTERIOSIS; BREAST CARCINOMA; BRONCHITIS; CANDIDIASIS; CELLULITIS; CEREBROVASCULAR ACCIDENT; CHOLECYSTITIS; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DEMYELINATING DISEASE; DEMYELINATION; DIGESTIVE SYSTEM CANCER; DRUG EFFICACY; DRUG FATALITY; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; FRACTURE; FUNGEMIA; HEALTH ASSESSMENT QUESTIONNAIRE; HEART FAILURE; HEART INFARCTION; HERPES ZOSTER; HUMAN; INFECTION; LEUKEMIA; LUNG CANCER; LUNG CARCINOMA; LYMPHOMA; MAJOR CLINICAL STUDY; MALE; MELANOMA; MENINGOENCEPHALITIS; MYCOBACTERIOSIS; MYELOID LEUKEMIA; NORTH AMERICA; OPPORTUNISTIC INFECTION; PNEUMONIA; POPULATION; PROSTATE; PROTEIN BLOOD LEVEL; RESPIRATORY FAILURE; RHEUMATOID ARTHRITIS; RISK BENEFIT ANALYSIS; SEPSIS; SEPTICEMIA; SIDE EFFECT; SOLID TUMOR; ADOLESCENT; CHEMICALLY INDUCED DISORDER; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DISABILITY; DOUBLE BLIND PROCEDURE; DRUG ADMINISTRATION; HOSPITALIZATION; KAPLAN MEIER METHOD; MIDDLE AGED; MULTICENTER STUDY; NEOPLASM; PREDICTIVE VALUE; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; RISK ASSESSMENT; RISK FACTOR; TIME; TREATMENT OUTCOME;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; DISABILITY EVALUATION; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; IMMUNOGLOBULIN G; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; NEOPLASMS; NORTH AMERICA; OPPORTUNISTIC INFECTIONS; PREDICTIVE VALUE OF TESTS; QUESTIONNAIRES; RECEPTORS, TUMOR NECROSIS FACTOR; RISK ASSESSMENT; RISK FACTORS; SEPSIS; SEVERITY OF ILLNESS INDEX; TIME FACTORS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 79960141758     PISSN: 00043591     EISSN: 21514658     Source Type: Journal    
DOI: 10.1002/acr.20372     Document Type: Article

References (22)

1. Bathon JM, Martin RW, Fleischmann RM, Tesser JR, Schiff MH, Keystone EC, et al. A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis. N Engl J Med 2000;343:1586-93. (Pubitemid 32162981)
2. Genovese MC, Bathon JM, Martin RW, Fleischmann RM, Tesser JR, Schiff MH, et al. Etanercept versus methotrexate in patients with early rheumatoid arthritis: two-year radio-graphic and clinical outcomes. Arthritis Rheum 2002;46: 1443-50. (Pubitemid 34620189)
3. Klareskog L, Gaubitz M, Rodriguez-Valverde V, Malaise M, Dougados M, Wajdula J. A long-term, open-label trial of the safety and efficacy of etanercept (Enbrel) in patients with rheumatoid arthritis not treated with other disease-modifying antirheumatic drugs. Ann Rheum Dis 2006;65:1578-84. (Pubitemid 44799668)
4. Moreland LW, Baumgartner SW, Schiff MH, Tindall EA, Fleischmann RM, Weaver AL, et al. Treatment of rheumatoid arthritis with a recombinant human tumor necrosis factor receptor (p75)-Fc fusion protein. N Engl J Med 1997;337: 141-7. (Pubitemid 27306284)
5. Moreland LW, Schiff MH, Baumgartner SW, Tindall EA, Fleischmann RM, Bulpitt KJ, et al. Etanercept therapy in rheumatoid arthritis: a randomized, controlled trial. Ann Intern Med 1999;130:478-86. (Pubitemid 29135800)
6. Moreland LW, Cohen SB, Baumgartner SW, Tindall EA, Bul-pitt K, Martin R, et al. Long-term safety and efficacy of etan-ercept in patients with rheumatoid arthritis. J Rheumatol 2001;28:1238-44. (Pubitemid 32510493)
7. Moreland LW, Weinblatt ME, Keystone EC, Kremer JM, Martin RW, Schiff MH, et al. Etanercept treatment in adults with established rheumatoid arthritis: 7 years of clinical experience. J Rheumatol 2006;33:854-61.
8. Weinblatt ME, Kremer JM, Bankhurst AD, Bulpitt KJ, Fleisch-mann RM, Fox RI, et al. A trial of etanercept, a recombinant tumor necrosis factor receptor:Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate. N Engl J Med 1999;340:253-9. (Pubitemid 29063266)
9. US Government Printing Office. Code of Federal Regulations, title 21: food and drugs. 2010. URL: http://edocket.access.gpo.gov/cfr-2002/aprqtr/ 21cfr310.305.htm.
10. Centers for Disease Control and Prevention Wonder Online Database. Revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults, United States. 1992. URL: http://wonder.cdc.gov/wonder/help/AIDS/MMWR-12-18-1992.html.
11. Felson DT, Anderson JJ, Boers M, Bombardier C, Furst D, Goldsmith C, et al. American College of Rheumatology preliminary definition of improvement in rheumatoid arthritis. Arthritis Rheum 1995;38:727-35.
12. Angus DC, Linde-Zwirble WT, Lidicker J, Clermont G, Car-cillo J, Pinsky MR. Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care. Crit Care Med 2001;29:1303-10. (Pubitemid 32641789)
13. Kochanek KD, Smith BL, Anderson RN. Deaths: preliminary data for 1999. Natl Vital Stat Rep 2001;49:1-48.
14. Doran MF, Pond GR, Crowson CS, O'Fallon WM, Gabriel SE. Trends in incidence and mortality in rheumatoid arthritis in Rochester, Minnesota, over a forty-year period. Arthritis Rheum 2002;46:625-31. (Pubitemid 34214244)
15. Doran MF, Crowson CS, Pond GR, O'Fallon WM, Gabriel SE. Frequency of infection in patients with rheumatoid arthritis compared with controls: a population-based study. Arthritis Rheum 2002;46:2287-93.
16. Singh G, Ramey D, Rausch P, Schettler J. Serious infection rate in rheumatoid arthritis: relationship to immunosuppres-sive use abstract. Arthritis Rheum 1999;42 Suppl:S242.
17. Askling J, Fored CM, Baecklund E, Brandt L, Backlin C, Ek-bom A, et al. Haematopoietic malignancies in rheumatoid arthritis: lymphoma risk and characteristics after exposure to tumour necrosis factor antagonists. Ann Rheum Dis 2005;64: 1414-20. (Pubitemid 41623850)
18. Baecklund E, Iliadou A, Askling J, Ekbom A, Backlin C, Granath F, et al. Association of chronic inflammation, not its treatment, with increased lymphoma risk in rheumatoid arthritis. Arthritis Rheum 2006;54:692-701.
19. Baecklund E, Ekbom A, Sparen P, Feltelius N, Klareskog L. Disease activity and risk of lymphoma in patients with rheumatoid arthritis: nested case-control study. BMJ 1998;317: 180-1. (Pubitemid 28325543)
20. Baumgartner SW, Fleischmann RM, Moreland LW, Schiff MH, Markenson J, Whitmore JB. Etanercept (Enbrel) in patients with rheumatoid arthritis with recent onset versus established disease: improvement in disability. J Rheumatol 2004;31:1532-7. (Pubitemid 39006633)
21. Wallis RS, Broder MS, Wong JY, Hanson ME, Beenhouwer DO. Granulomatous infectious diseases associated with tumor necrosis factor antagonists. Clin Infect Dis 2004;38:1261-5. (Pubitemid 38608568)
22. Dixon WG, Watson KD, Lunt M, Mercer LK, British Society for Rheumatology Biologics Register Control Centre Consortium, Hyrich KL, et al, on behalf of the British Society for Rheumatology Biologics Register. Influence of anti-tumor necrosis factor therapy on cancer incidence in patients with rheumatoid arthritis who have had a prior malignancy: results from the British Society for Rheumatology Biologics Register. Arthritis Care Res (Hoboken) 2010;62:755-63.